ClinicalTrials.gg
CompletedNCT01664247Updated Sep 25, 2017Results posted

The Effect of Insulin Degludec in Combination With Liraglutide and Metformin in Subjects With Type 2 Diabetes Qualifying for Treatment Intensification

A Phase 3 interventional study of insulin degludec and placebo in Diabetes and Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S. Completed at 132 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-09-25.

Primary conditionDiabetes Mellitus, Type 2Registry: Diabetes MellitusReclassifiedWhy we changed it
Registry
Diabetes Mellitus — the first condition term the registry derived for this study.
ClinicalTrials.gg
Diabetes Mellitus, Type 2
Why
  1. The study's listed conditions name Diabetes Mellitus, Type 2, a narrower term within Diabetes Mellitus.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
346
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 70 studies testing insulin degludec in Diabetes Mellitus, Type 2 — 4 open to participants now, 4 under way, 2 of them phase 3. insulin degludec · Diabetes Mellitus, Type 2.

Enrollment
37th of 70
346 · median 384
Started
2012
with 5 others
Phase 3
49 of 70
2 open now
Registered
29th of 70
by date
Lead sponsor
56 of 70
Novo Nordisk A/S

Among the 70 studies testing insulin degludec in Diabetes Mellitus, Type 2, this one is the 37th largest by enrollment, is one of 6 that started in 2012, is one of 49 in phase 3, and was the 29th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

4 of the 70 studies testing insulin degludec in Diabetes Mellitus, Type 2 are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About insulin degludec

insulin degludec: first FDA approval 2015 (RYZODEG 70/30), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 70 studies testing insulin degludec in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

This trial is conducted in Africa, Asia, Europe and North America. The purpose of the trial is to investigate the effect of insulin degludec (IDeg) in combination with liraglutide (Lira) and metformin (at least 1500 mg daily or maximum tolerated dose) in subjects with type 2 diabetes qualifying for treatment intensification.

03

Conditions studied

  • Diabetes
  • Diabetes Mellitus, Type 2

Browse trials for

04

In context

Diabetes Mellitus, Type 2 Reclassified

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

This study's enrollment of 346 is above the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.

Browse Diabetes Mellitus, Type 2 studies →

Lead sponsor

Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.

Compared within Diabetes Mellitus, Type 2, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Type 2 diabetes
  • Insulin naïve
  • Ongoing treatment with metformin or metformin in combination with either sulphonylurea (SU), glinides, dipeptidyl peptidase-IV (DPP-IV) inhibitors or exenatide (only twice daily (BID))
  • Glycosylated () (by central laboratory analysis): a. 7.5-10.0 % (both inclusive) for subjects on metformin monotherapy, b. 7.0-9.0 % (both inclusive) for subjects on metformin in combination with either SU, glinides, DPP-IV inhibitors or exenatide (only BID)

Exclusion criteria

Exclusion Criteria:

  • Treatment with glucose-lowering agent(s) other than stated in the inclusion criteria within 12 weeks
  • Calcitonin equal to or above 50 pg/mL
  • Stroke; heart failure (NYHA) class III or IV; myocardial infarction; unstable angina pectoris; or coronary arterial bypass graft or angioplasty; all within 24 weeks
  • Current or past (within the last 5 years) malignant neoplasms (except basal cell and squamous cell carcinoma)
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
346 participants (actual)

Study arms

  • Experimental
    IDeg + Lira

    Drug: insulin degludec · Drug: liraglutide

  • Experimental
    Placebo + Lira

    Drug: placebo · Drug: liraglutide

Interventions

  • Administered s.c. (under the skin) once daily. Dose individually adjusted.

  • Drugplacebo

    Administered s.c. (under the skin) once daily. Dose individually adjusted.

  • Administered s.c. (under the skin) once daily. Dose: 1.8 mg.

07

What researchers measure

Primary outcomes

  1. Change From Baseline in Glycosylated Haemoglobin (HbA1c) (%)

    Change from baseline in HbA1c after 26 weeks of treatment

    Time frame: Week 0, week 26

Secondary outcomes

  1. Change From Baseline in Fasting Plasma Glucose (FPG)

    Change from baseline in FPG after 26 weeks of treatment

    Time frame: Week 0, week 26

  2. Number of Responders for HbA1c (Below 7.0 %)

    Number of responders for HbA1c below 7.0%, after 26 weeks of randomised treatment.

    Time frame: After 26 weeks of randomised treatment.

  3. Change From Baseline in Mean Pre-breakfast Measurements Used for Titration

    Change from baseline after 26 weeks of treatment in the average of the pre-breakfast self measured plasma glucose (SMPG) measured on the day of the contact and the two days immediately prior to the contact. The least squares means presented are the estimated values after 26 weeks of treatment and the statistical analysis presents the treatment difference of the change from baseline values as the model is adjusted for baseline.

    Time frame: Week 0, week 26

  4. Change From Baseline in 8-point Profile

    The change from baseline in the 8-point SMPG profile after 26 weeks of randomised treatment. The least squares means presented are the estimated values after 26 weeks of treatment and the statistical analysis presents the treatment difference of the change from baseline values as the model is adjusted for baseline.

    Time frame: Week 0, week 26

  5. Change From Baseline in Mean of the 8-point Profile

    Change from baseline in mean of the 8-point profile after 26 weeks of randomised treatment.

    Time frame: Week 0, week 26

  6. Number of Hypoglycaemic Episodes

    Number of confirmed hypoglycaemic episodes from week 0 to 26 weeks of randomised treatment. A hypoglycaemic episode was defined as treatment emergent if the onset of the episode occurred after the first administration of investigational medicinal product and no later than 7 days after the last day on trial product. Confirmed hypoglycaemic episodes consisted of severe hypoglycaemia or minor hypoglycaemic episodes.

    Time frame: Weeks 0 - 26

  7. Number of Adverse Events

    Number of treatment emergent AEs (TEAEs) from week 0 to week 26 of the randomised treatment. A TEAE was defined as an event that had onset date on or after the first day of exposure to randomised treatment and no later than 7 days after the last day of randomised treatment.

    Time frame: Weeks 0 - 26

  8. Change From Baseline in Patient Reported Health-related Quality of Life Using the Short-Form 36 Health Survey Version 2 (SF-36®v2)

    Change in subject's quality of life was evaluated using the Short-Form 36 Health Survey version 2 (SF-36®v2). Evaluations were performed at baseline and at the last treatment visit (week 26). SF-36 was assessed on a scale range of 0.65 to 80.73 for physical health and -8.81 to 81.65 for mental health respectively, where higher scores indicated a better quality of life. 0-100 scores from the SF-36 were converted to a norm-based score using a T-score transformation in order to obtain a direct interpretation in relation to the distribution of the scores in the 1998 U.S. general population.

    Time frame: Week 0, week 26

08

Results

Posted Apr 20, 2016

Participant flow

The trial was conducted at 129 sites in 11 countries randomised subjects: Canada (7), France (10), Germany (8), Israel (6), Italy (7), Serbia (7), South Africa (6), Ukraine (4), United Arab Emirates (3), United Kingdom (6), and United States (65).

Participant flow — Overall Study
MilestoneIDegPlacebo
Started174172
Exposed173170
Completed160131
Not completed1441
Withdrew: Adverse event53
Withdrew: Protocol violation35
Withdrew: Withdrawal criteria14
Withdrew: Unclassified529

Outcome measures

PrimaryChange From Baseline in Glycosylated Haemoglobin (HbA1c) (%)

Change from baseline in HbA1c after 26 weeks of treatment

Time frame:
Week 0, week 26
Reported as:
Least squares mean · percentage of glycosylated haemoglobin
Change From Baseline in Glycosylated Haemoglobin (HbA1c) (%)
percentage of glycosylated haemoglobinIDegPlacebo
Change From Baseline in Glycosylated Haemoglobin (HbA1c) (%)-0.99 ± 0.08-0.07 ± 0.08
SecondaryChange From Baseline in Fasting Plasma Glucose (FPG)

Change from baseline in FPG after 26 weeks of treatment

Time frame:
Week 0, week 26
Reported as:
Mean · mmol/L
Change From Baseline in Fasting Plasma Glucose (FPG)
mmol/LIDegPlacebo
Change From Baseline in Fasting Plasma Glucose (FPG)-2.60 ± 2.91-0.28 ± 2.44
SecondaryNumber of Responders for HbA1c (Below 7.0 %)

Number of responders for HbA1c below 7.0%, after 26 weeks of randomised treatment.

Time frame:
After 26 weeks of randomised treatment.
Reported as:
Number · percentage (%) of subjects
Number of Responders for HbA1c (Below 7.0 %)
percentage (%) of subjectsIDegPlacebo
Number of Responders for HbA1c (Below 7.0 %)77.635.5
SecondaryChange From Baseline in Mean Pre-breakfast Measurements Used for Titration

Change from baseline after 26 weeks of treatment in the average of the pre-breakfast self measured plasma glucose (SMPG) measured on the day of the contact and the two days immediately prior to the contact. The least squares means presented are the estimated values after 26 weeks of treatment and the statistical analysis presents the treatment difference of the change from baseline values as the model is adjusted for baseline.

Time frame:
Week 0, week 26
Reported as:
Least squares mean · mmol/L
Change From Baseline in Mean Pre-breakfast Measurements Used for Titration
mmol/LIDegPlacebo
Change From Baseline in Mean Pre-breakfast Measurements Used for Titration5.88 ± 0.148.23 ± 0.15
Statistical analysis
  • IDeg vs Placebo · ANOVA · p = <.0001 · Mean difference (final values): -2.34 · 95% CI -2.67 to -2.01The treatment contrast estimated was IDeg - Placebo.
SecondaryChange From Baseline in 8-point Profile

The change from baseline in the 8-point SMPG profile after 26 weeks of randomised treatment. The least squares means presented are the estimated values after 26 weeks of treatment and the statistical analysis presents the treatment difference of the change from baseline values as the model is adjusted for baseline.

Time frame:
Week 0, week 26
Reported as:
Least squares mean · mmol/L
Change From Baseline in 8-point Profile
mmol/LIDegPlacebo
Before breakfast, N=170, 1645.85 ± 0.158.54 ± 0.16
90 min after breakfast, N=153, 1487.65 ± 0.249.75 ± 0.25
Before lunch, N=151,1496.33 ± 0.188.34 ± 0.19
90 min after lunch, N=152,1507.73 ± 0.219.67 ± 0.21
Before evening meal, N=154,1486.77 ± 0.209.51 ± 0.21
90 mins after evening meal, N=147,1457.93 ± 0.219.65 ± 0.22
Before bedtime, N=148, 1427.21 ± 0.208.95 ± 0.21
Before breakfast the next day, N=164,1616.05 ± 0.178.55 ± 0.18
Statistical analysis
  • IDeg vs Placebo · Mixed Models Analysis · p = <.0001 · Mean difference (final values): -2.69 · 95% CI -3.04 to -2.34The treatment contrast estimated was IDeg - Placebo
  • IDeg vs Placebo · Mixed Models Analysis · p = <.0001 · Mean difference (final values): -2.09 · 95% CI -2.71 to -1.48The treatment contrast estimated was IDeg - Placebo.
  • IDeg vs Placebo · Mixed Models Analysis · p = <.0001 · Mean difference (final values): -2.01 · 95% CI -2.47 to -1.56The treatment contrast estimated was IDeg - Placebo.
  • IDeg vs Placebo · Mixed Models Analysis · p = <.0001 · Median difference (final values): -1.93 · 95% CI -2.46 to -1.40The treatment contrast estimated was IDeg - Placebo.
  • IDeg vs Placebo · Mixed Models Analysis · p = <.0001 · Mean difference (final values): -1.74 · 95% CI -2.25 to -1.23The treatment contrast estimated was IDeg - Placebo.
  • IDeg vs Placebo · Mixed Models Analysis · p = <.0001 · Mean difference (final values): -1.72 · 95% CI -2.26 to -1.18The treatment contrast estimated was IDeg - Placebo.
  • IDeg vs Placebo · Mixed Models Analysis · p = <.0001 · Mean difference (final values): -1.75 · 95% CI -2.27 to -1.23The treatment contrast estimated was IDeg - Placebo.
  • IDeg vs Placebo · Mixed Models Analysis · p = <.0001 · Mean difference (final values): -2.50 · 95% CI -2.91 to -2.09The treatment contrast estimated was IDeg - Placebo.
SecondaryChange From Baseline in Mean of the 8-point Profile

Change from baseline in mean of the 8-point profile after 26 weeks of randomised treatment.

Time frame:
Week 0, week 26
Reported as:
Mean · mmol/L
Change From Baseline in Mean of the 8-point Profile
mmol/LIDegPlacebo
Change From Baseline in Mean of the 8-point Profile-2.3 ± 1.8-0.5 ± 1.7
SecondaryNumber of Hypoglycaemic Episodes

Number of confirmed hypoglycaemic episodes from week 0 to 26 weeks of randomised treatment. A hypoglycaemic episode was defined as treatment emergent if the onset of the episode occurred after the first administration of investigational medicinal product and no later than 7 days after the last day on trial product. Confirmed hypoglycaemic episodes consisted of severe hypoglycaemia or minor hypoglycaemic episodes.

Time frame:
Weeks 0 - 26
Reported as:
Number · events
Number of Hypoglycaemic Episodes
eventsIDegPlacebo
Number of Hypoglycaemic Episodes479
SecondaryNumber of Adverse Events

Number of treatment emergent AEs (TEAEs) from week 0 to week 26 of the randomised treatment. A TEAE was defined as an event that had onset date on or after the first day of exposure to randomised treatment and no later than 7 days after the last day of randomised treatment.

Time frame:
Weeks 0 - 26
Reported as:
Number · events
Number of Adverse Events
eventsIDegPlacebo
Number of Adverse Events285252
SecondaryChange From Baseline in Patient Reported Health-related Quality of Life Using the Short-Form 36 Health Survey Version 2 (SF-36®v2)

Change in subject's quality of life was evaluated using the Short-Form 36 Health Survey version 2 (SF-36®v2). Evaluations were performed at baseline and at the last treatment visit (week 26). SF-36 was assessed on a scale range of 0.65 to 80.73 for physical health and -8.81 to 81.65 for mental health respectively, where higher scores indicated a better quality of life. 0-100 scores from the SF-36 were converted to a norm-based score using a T-score transformation in order to obtain a direct interpretation in relation to the distribution of the scores in the 1998 U.S. general population.

Time frame:
Week 0, week 26
Reported as:
Mean · T-scores
Change From Baseline in Patient Reported Health-related Quality of Life Using the Short-Form 36 Health Survey Version 2 (SF-36®v2)
T-scoresIDegPlacebo
Physical health0.5 ± 6.30.0 ± 6.2
Mental health0.6 ± 8.1-0.7 ± 8.8

Adverse events

Collected over The adverse events were collected in a time frame of 26 weeks + 7 days follow up. Adverse event with an onset date on or after the first day of exposure to randomised treatment and no later than 7 days after the last day of randomised treatment.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
IDeg—6/173 (3.5%)33/173 (19.1%)
Placebo—9/170 (5.3%)32/170 (18.8%)
Most frequent serious events
Showing 10 of 20
Most frequent serious events
EventIDegPlacebo
Atrial fibrillationCardiac disorders0/1731/170
Cardiac failureCardiac disorders0/1731/170
Cardiac failure congestiveCardiac disorders0/1731/170
TachycardiaCardiac disorders0/1731/170
Ventricular tachycardiaCardiac disorders0/1731/170
Upper respiratory tract infectionInfections and infestations0/1731/170
UrosepsisInfections and infestations0/1731/170
Humerus fractureInjury, poisoning and procedural complications0/1731/170
Malignant melanomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1731/170
Transitional cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1731/170
Most frequent other events
Most frequent other events
EventIDegPlacebo
NasopharyngitisInfections and infestations14/17311/170
DiarrhoeaGastrointestinal disorders10/17313/170
Lipase increasedInvestigations10/17313/170

Baseline characteristics

Age, Continuous
Age, Continuous(years)IDegPlaceboTotal
Mean57.0 ± 10.057.3 ± 9.457.2 ± 9.7
Sex: Female, Male
Sex: Female, Male(Participants)IDegPlaceboTotal
Female7668144
Male98104202
Glycosylated haemoglobin (HbA1c)
Glycosylated haemoglobin (HbA1c)(percentage of glycosylated haemoglobin)IDegPlaceboTotal
Mean7.5 ± 0.67.6 ± 0.67.6 ± 0.6
Fasting plasma glucose (FPG)
Fasting plasma glucose (FPG)(mmol/L)IDegPlaceboTotal
Mean8.7 ± 2.19.1 ± 2.28.9 ± 2.2
09

Study locations

132 sites
  • Novo Nordisk Investigational Site
    Anaheim, California 92801, United States
  • Novo Nordisk Investigational Site
    Concord, California 94520, United States
  • Novo Nordisk Investigational Site
    Escondido, California 92025, United States
  • Novo Nordisk Investigational Site
    Fresno, California 93720, United States
  • Novo Nordisk Investigational Site
    Huntington Beach, California 92648, United States
  • Novo Nordisk Investigational Site
    La Jolla, California 92037, United States
  • Novo Nordisk Investigational Site
    Los Angeles, California 90057, United States
  • Novo Nordisk Investigational Site
    Monterey, California 93940, United States
  • Novo Nordisk Investigational Site
    Spring Valley, California 91978, United States
  • Novo Nordisk Investigational Site
    Walnut Creek, California 94598, United States
  • Novo Nordisk Investigational Site
    Boynton Beach, Florida 33472, United States
  • Novo Nordisk Investigational Site
    Clearwater, Florida 33765, United States
  • Novo Nordisk Investigational Site
    Hollywood, Florida 33021, United States
  • Novo Nordisk Investigational Site
    Jacksonville, Florida 32207, United States
  • Novo Nordisk Investigational Site
    Miami, Florida 33135, United States
  • Novo Nordisk Investigational Site
    Miami, Florida 33156, United States
  • Novo Nordisk Investigational Site
    New Port Richey, Florida 34652, United States
  • Novo Nordisk Investigational Site
    Palm Harbor, Florida 34684, United States
  • Novo Nordisk Investigational Site
    Tampa, Florida 33603, United States
  • Novo Nordisk Investigational Site
    Decatur, Georgia 30033, United States
  • Novo Nordisk Investigational Site
    Perry, Georgia 31069, United States
  • Novo Nordisk Investigational Site
    Roswell, Georgia 30076, United States
  • Novo Nordisk Investigational Site
    Chicago, Illinois 60607, United States
  • Novo Nordisk Investigational Site
    Springfield, Illinois 62711, United States
  • Novo Nordisk Investigational Site
    Topeka, Kansas 66606, United States
  • Novo Nordisk Investigational Site
    Paducah, Kentucky 42003, United States
  • Novo Nordisk Investigational Site
    Metairie, Louisiana 70002, United States
  • Novo Nordisk Investigational Site
    Hyattsville, Maryland 20782, United States
  • Novo Nordisk Investigational Site
    Buckley, Michigan 49620, United States
  • Novo Nordisk Investigational Site
    Chesterfield, Missouri 63017-3632, United States
  • Novo Nordisk Investigational Site
    Henderson, Nevada 89052-2649, United States
  • Novo Nordisk Investigational Site
    Nashua, New Hampshire 03063, United States
  • Novo Nordisk Investigational Site
    Lawrenceville, New Jersey 08648, United States
  • Novo Nordisk Investigational Site
    Toms River, New Jersey 08755-8050, United States
  • Novo Nordisk Investigational Site
    Northport, New York 11768, United States
  • Novo Nordisk Investigational Site
    Smithtown, New York 11787, United States
  • Novo Nordisk Investigational Site
    West Seneca, New York 14224, United States
  • Novo Nordisk Investigational Site
    Chapel Hill, North Carolina 27517, United States
  • Novo Nordisk Investigational Site
    Greensboro, North Carolina 27408, United States
  • Novo Nordisk Investigational Site
    Morehead City, North Carolina 28557, United States
  • Novo Nordisk Investigational Site
    Cincinnati, Ohio 45255, United States
  • Novo Nordisk Investigational Site
    Dayton, Ohio 45439, United States
  • Novo Nordisk Investigational Site
    Franklin, Ohio 45005, United States
  • Novo Nordisk Investigational Site
    Philadelphia, Pennsylvania 19152, United States
  • Novo Nordisk Investigational Site
    Greer, South Carolina 29651, United States
  • Novo Nordisk Investigational Site
    Simpsonville, South Carolina 29681, United States
  • Novo Nordisk Investigational Site
    Chattanooga, Tennessee 37404-1192, United States
  • Novo Nordisk Investigational Site
    Chattanooga, Tennessee 37411, United States
  • Novo Nordisk Investigational Site
    Humboldt, Tennessee 38343, United States
  • Novo Nordisk Investigational Site
    Kingsport, Tennessee 37660, United States
  • Novo Nordisk Investigational Site
    Nashville, Tennessee 37212, United States
  • Novo Nordisk Investigational Site
    Austin, Texas 78731, United States
  • Novo Nordisk Investigational Site
    Dallas, Texas 75230, United States
  • Novo Nordisk Investigational Site
    Dallas, Texas 75231, United States
  • Novo Nordisk Investigational Site
    Dallas, Texas 75246, United States
  • Novo Nordisk Investigational Site
    Dallas, Texas 75390, United States
  • Novo Nordisk Investigational Site
    Houston, Texas 77030-2703, United States
  • Novo Nordisk Investigational Site
    Irving, Texas 75061-2210, United States
  • Novo Nordisk Investigational Site
    Lubbock, Texas 79423, United States
  • Novo Nordisk Investigational Site
    Round Rock, Texas 78681, United States
  • Novo Nordisk Investigational Site
    San Antonio, Texas 78224, United States
  • Novo Nordisk Investigational Site
    Sugar Land, Texas 77478, United States
  • Novo Nordisk Investigational Site
    Saint George, Utah 84790, United States
  • Novo Nordisk Investigational Site
    Salt Lake City, Utah 84107, United States
  • Novo Nordisk Investigational Site
    Newport News, Virginia 23606, United States
  • Novo Nordisk Investigational Site
    Spokane, Washington 99218, United States
  • Novo Nordisk Investigational Site
    Milwaukee, Wisconsin 53209, United States
  • Novo Nordisk Investigational Site
    Delta, British Columbia V4K 2K5, Canada
  • Novo Nordisk Investigational Site
    Brampton, Ontario L6T 0G1, Canada
  • Novo Nordisk Investigational Site
    London, Ontario N6P 1A9, Canada
  • Novo Nordisk Investigational Site
    Ottawa, Ontario K1N 1A2, Canada
  • Novo Nordisk Investigational Site
    Toronto, Ontario M5C 2T2, Canada
  • Novo Nordisk Investigational Site
    Toronto, Ontario M9V 4B4, Canada
  • Novo Nordisk Investigational Site
    Quebec, G3K 2P8, Canada
  • Novo Nordisk Investigational Site
    Bron, 69677, France
  • Novo Nordisk Investigational Site
    Corbeil Essonnes, 91106, France
  • Novo Nordisk Investigational Site
    Le Creusot, 71200, France
  • Novo Nordisk Investigational Site
    Merignac, 33700, France
  • Novo Nordisk Investigational Site
    Nanterre, 92014, France
  • Novo Nordisk Investigational Site
    Niort, 79021, France
  • Novo Nordisk Investigational Site
    Pau, 64000, France
  • Novo Nordisk Investigational Site
    Pointe à Pitre, 97159, France
  • Novo Nordisk Investigational Site
    Saint Herblain, 44800, France
  • Novo Nordisk Investigational Site
    Saint-denis de La Reunion, 97405, France
  • Novo Nordisk Investigational Site
    Venissieux, 69200, France
  • Novo Nordisk Investigational Site
    Berlin, 12163, Germany
  • Novo Nordisk Investigational Site
    Falkensee, 14612, Germany
  • Novo Nordisk Investigational Site
    Friedrichsthal, 66299, Germany
  • Novo Nordisk Investigational Site
    Hamburg, 22607, Germany
  • Novo Nordisk Investigational Site
    Hohenmölsen, 06679, Germany
  • Novo Nordisk Investigational Site
    Kirn, 55606, Germany
  • Novo Nordisk Investigational Site
    Ludwigshafen, 67059, Germany
  • Novo Nordisk Investigational Site
    St. Ingbert, 66386, Germany
  • Novo Nordisk Investigational Site
    Völklingen, 66333, Germany
  • Novo Nordisk Investigational Site
    Beer Sheva, 84101, Israel
  • Novo Nordisk Investigational Site
    Haifa, 31096, Israel
  • Novo Nordisk Investigational Site
    Holon, 58100, Israel
  • Novo Nordisk Investigational Site
    Jerusalem, 91120, Israel
  • Novo Nordisk Investigational Site
    Rishon Le Zion, 75650, Israel
  • Novo Nordisk Investigational Site
    Tel Hashomer, 52621, Israel

Showing the first 100 of 132 sites across 11 countries. Choose a country and city above to see the rest.

10

References and documents

Publications

  • Aroda VR, Bailey TS, Cariou B, Kumar S, Leiter LA, Raskin P, Zacho J, Andersen TH, Philis-Tsimikas A. Effect of adding insulin degludec to treatment in patients with type 2 diabetes inadequately controlled with metformin and liraglutide: a double-blind randomized controlled trial (BEGIN: ADD TO GLP-1 Study). Diabetes Obes Metab. 2016 Jul;18(7):663-70. doi: 10.1111/dom.12661. Epub 2016 May 2. Erratum In: Diabetes Obes Metab. 2016 Sep;18(9):952. doi: 10.1111/dom.12746. PubMed 26990378 ↗
11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2012 to primary completion in Dec 2013, 14 months.

Results were first posted in Apr 2016, 2 years 3 months after primary completion. A results delay was requested in Jan 2014.

Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 14 months is below that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 10, 2012
First posted
Aug 14, 2012
StartActual
Oct 1, 2012
Primary completionActual
Dec 31, 2013
CompletionActual
Dec 31, 2013
Results delay requested
Jan 24, 2014
Results first posted
Apr 20, 2016
Last update
Sep 25, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 25, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT01664247
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Aug 14, 2012
Start date
Oct 1, 2012
Primary completion
Dec 31, 2013
Completion
Dec 31, 2013
Results posted
Apr 20, 2016
Last update
Sep 25, 2017

Study contacts

Global Clinical Registry (GCR, 1452)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Insulin degludec

Start the discussion